Copy into your RSS Reader
Copy into your Podcast App
The schizophrenia drug Risperdal was at the heart of government investigations into improper marketing that stretched back more than a decade.
JB Reed/Bloomberg via Getty Images
November 4, 2013 A company subsidiary pleaded guilty to a misdemeanor charge stemming from the promotion of antipsychotic Risperdal for the treatment of dementia in elderly patients. The Food and Drug Administration never approved the drug for that use.
April 11, 2012 An Arkansas judge's penalty is just the latest legal setback related to the company's marketing of Risperdal, an antipsychotic drug. Among the drug's possible side effects are weight gain and increased risk for diabetes.
NPR thanks our sponsors
Become an NPR sponsor